U.S. flag

An official website of the United States government

NM_000540.3(RYR1):c.5484C>T (p.Asp1828=) AND RYR1-related disorder

Germline classification:
Likely benign (2 submissions)
Last evaluated:
Jan 17, 2024
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001469617.9

Allele description [Variation Report for NM_000540.3(RYR1):c.5484C>T (p.Asp1828=)]

NM_000540.3(RYR1):c.5484C>T (p.Asp1828=)

Gene:
RYR1:ryanodine receptor 1 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
19q13.2
Genomic location:
Preferred name:
NM_000540.3(RYR1):c.5484C>T (p.Asp1828=)
HGVS:
  • NC_000019.10:g.38486139C>T
  • NG_008866.1:g.57440C>T
  • NM_000540.2:c.5484C>T
  • NM_000540.3:c.5484C>TMANE SELECT
  • NM_001042723.2:c.5484C>T
  • NP_000531.2:p.Asp1828=
  • NP_001036188.1:p.Asp1828=
  • LRG_766t1:c.5484C>T
  • LRG_766:g.57440C>T
  • NC_000019.9:g.38976779C>T
Links:
dbSNP: rs775744847
NCBI 1000 Genomes Browser:
rs775744847
Molecular consequence:
  • NM_000540.3:c.5484C>T - synonymous variant - [Sequence Ontology: SO:0001819]
  • NM_001042723.2:c.5484C>T - synonymous variant - [Sequence Ontology: SO:0001819]

Condition(s)

Name:
RYR1-related disorder
Synonyms:
RYR1-Related Disorders; RYR1-related condition
Identifiers:
MedGen: CN239331

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001673697Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Likely benign
(Jan 17, 2024)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV004715548PreventionGenetics, part of Exact Sciences
no assertion criteria provided
Likely benign
(Aug 2, 2023)
germlineclinical testing

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV001673697.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From PreventionGenetics, part of Exact Sciences, SCV004715548.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications).

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Nov 3, 2024